The study compared the i-FACTOR biologic bone graft to autologous bone delivered via interbody fusion cages in single and multilevel PLIF. A radiologic fusion rating for patients treated with i-FACTOR showed a 97.8 percent fusion rate, compared with an 82.2 fusion rate for patients treated with the autograft after one year.
The company received the CE Mark in 2008 for the i-FACTOR and is currently being evaluated by the FDA for clearance in the United States.
Read the Cerapedics release about i-FACTOR.
– Titan Spine Receives FDA 510(k) Clearance on PLIF Device
– Study: No Difference Between Iliac Bone Graft and Local bone Graft for PLIF
